drugset / Trial / NCT05940506
Phase II Study Evaluating the Efficacy and Safety of KX-826
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 in Chinese adult male patients with AGA.
Timeline
- Start
- 2020-09-28
- Primary completion
- 2021-07-08
- Completion
- 2021-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KX-826 | Unknown | 2.5 mg | Topical |
| Subject | KX-826 | Unknown | 5 mg | Topical |